Lenalidomid Sun (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, changing its substrate specificity. This triggers ubiquitination and degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that suppress malignant plasma cells and modify the immune environment.

The specific dose of Lenalidomid Sun is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Dosing regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Lenalidomid Sun is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception. The product is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant.

To order Lenalidomid Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally shows higher potency, a more favorable safety profile, and fewer peripheral neuropathy events. Pomalidomide is a newer IMiD with activity in some lenalidomide‑refractory cases, but it may have a higher risk of hematologic toxicity.

Lenalidomid Sun should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product protected from moisture and direct light. Do not store in the bathroom or near heat sources. Follow any additional handling instructions provided with the shipment to maintain product integrity.

Lenalidomid Sun is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals. Swallow the tablet whole; do not crush, split, or chew unless specifically instructed by a healthcare professional.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe cutaneous reactions like Stevens‑Johnson syndrome, and secondary malignancies such as acute leukemia. Patients should be monitored closely for signs of clotting, unusual skin changes, or new cancer symptoms, and report any concerns promptly to their healthcare provider.

Lenalidomid Sun should not be used by pregnant women or women who could become pregnant, because of its teratogenic potential (Category X). Patients with known hypersensitivity to lenalidomide or any component of the formulation should avoid it. Caution is also advised in individuals with severe renal impairment, uncontrolled infections, or a history of thromboembolic disease unless appropriate prophylaxis is in place.